TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05654454: Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-sma

Sponsor: Mabscale, LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 620 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,103,016

Rescue Site Savings

+$6,691,608

Unlock Full NCT05654454 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05654454 Rescue Dossier →